Goldman Sachs Group Inc Finch Therapeutics Group, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.36 - $56.4 $3,089 - $483,968	-8,581 Reduced 33.37%	17,135 $8,000
Q4 2022 Feb 13, 2023	SELL	$0.36 - $56.4 $3,089 - $483,968	-8,581 Reduced 33.37%	17,135 $8,000
Q3 2022 May 14, 2024	SELL	$1.75 - $51.3 $15,391 - $451,183	-8,795 Reduced 25.48%	25,716 $43,000
Q3 2022 Nov 10, 2022	SELL	$1.75 - $51.3 $15,391 - $451,183	-8,795 Reduced 25.48%	25,716 $0
Q2 2022 May 14, 2024	BUY	$1.91 - $5.11 $65,916 - $176,351	34,511 New	34,511 $98,000
Q2 2022 Aug 15, 2022	BUY	$1.91 - $5.11 $65,916 - $176,351	34,511 New	34,511 $98,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $575M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.